Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.

Solange Peters,Tony Mok,Shirish M. Gadgeel,Rafael Rosell,Rafal Dziadziuszko,Dong-Wan Kim,Maurice Pérol,Sai-Hong Ignatius Ou,Alice T. Shaw,Walter Bordogna,Vlatka Smoljanovic,Magalie Hilton,Thorsten Ruf,V. Archer,D. Ross Camidge

Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.

2020

Solange Peters
Tony Mok
Shirish M. Gadgeel
Rafael Rosell
Rafal Dziadziuszko
Dong-Wan Kim
Maurice Pérol
Sai-Hong Ignatius Ou
Alice T. Shaw
Walter Bordogna
Vlatka Smoljanovic
Magalie Hilton
Thorsten Ruf
V. Archer
D. Ross Camidge

9518Background: Final, mature PFS from the global phase III ALEX study (NCT02075840) of ALC vs CRZ in untreated, advanced/metastatic ALK+ NSCLC have been previously published: ALC 34.8 months (m) (...

Keywords:

Oncology
Crizotinib
overall survival
Alectinib
Internal medicine
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations